Education
About Us
Working with TipRanks
Follow Us
OncoCyte Corp (OCX)
NASDAQ:OCX
Total Valuation
OncoCyte has a market cap or net worth of $84.94M. The enterprise value is ―.
Market Cap$84.94M
Enterprise Value―
Share Statistics
OncoCyte has 28,599,285 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28,599,285
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
OncoCyte’s return on equity (ROE) is 4.94 and return on invested capital (ROIC) is -209.76%.
Return on Equity (ROE)4.94
Return on Assets (ROA)-1.73
Return on Invested Capital (ROIC)-209.76%
Return on Capital Employed (ROCE)-2.20
Revenue Per Employee40.89K
Profits Per Employee-1.32M
Employee Count46
Asset Turnover0.05
Inventory Turnover2.78
Valuation Ratios
The current PE Ratio of OncoCyte is -0.51. OncoCyte’s PEG ratio is -4.03.
PE Ratio-0.51
PS Ratio0.00
PB Ratio-4.55
Price to Fair Value-2.53
Price to FCF-3.23
Price to Operating Cash Flow-2.69
PEG Ratio-4.03
Income Statement
In the last 12 months, OncoCyte had revenue of 1.88M and earned -60.66M in profits. Earnings per share was -4.64.
Revenue1.88M
Gross Profit740.00K
Operating Income-61.04M
Pretax Income-60.66M
Net Income-60.66M
EBITDA-59.02M
Earnings Per Share (EPS)-4.64
Cash Flow
In the last 12 months, operating cash flow was -20.71M and capital expenditures -214.00K, giving a free cash flow of -20.93M billion.
Operating Cash Flow-20.71M
Free Cash Flow-20.93M
Free Cash Flow per Share-0.73
Dividends & Yields
OncoCyte pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change10.41%
50-Day Moving Average3.00
200-Day Moving Average2.83
Relative Strength Index (RSI)46.57
Average Volume (3m)38.70K
Important Dates
OncoCyte upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
OncoCyte as a current ratio of 1.62, with Debt / Equity ratio of -29.85%
Current Ratio1.62
Quick Ratio1.56
Debt to Market Cap0.12
Net Debt to EBITDA0.08
Interest Coverage Ratio-726.68
Taxes
In the past 12 months, OncoCyte has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
OncoCyte EV to EBITDA ratio is -0.44, with an EV/FCF ratio of -1.26.
EV to Sales13.90
EV to EBITDA-0.44
EV to Free Cash Flow-1.26
EV to Operating Cash Flow-1.26
Balance Sheet
OncoCyte has $8.64M in cash and marketable securities with $3.66M in debt, giving a net cash position of -$4.97M billion.
Cash & Marketable Securities$8.64M
Total Debt$3.66M
Net Cash-$4.97M
Net Cash Per Share-$0.17
Tangible Book Value Per Share-$2.06
Margins
Gross margin is 19.14%, with operating margin of -3245.14%, and net profit margin of -3225.04%.
Gross Margin19.14%
Operating Margin-3245.14%
Pretax Margin-3225.04%
Net Profit Margin-3225.04%
EBITDA Margin-3137.43%
EBIT Margin-3220.57%
Analyst Forecast
The average price target for OncoCyte is $6.13, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.13
Price Target Upside106.40% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast178.08%
EPS Growth Forecast86.04%